© 2026 Sinochem Nanjing Corporation,
All Right Reserved
In the early 2000s, diabetes and heart disease continued to challenge both patients and physicians. Glucose-lowering drugs often meant injections, rigid routines, and stubborn side effects. Researchers hunted for answers beyond the pancreas, hoping to curb sugar at its exit routes, too. Sodium-glucose co-transporter (SGLT) inhibitors promised a new way—blocking sugar reabsorption in the kidneys. By 2013, the dual SGLT1 and SGLT2 inhibitor sotagliflozin stepped up, showing promise not just for type 2 diabetes but also for type 1 diabetes. Unlike single-target drugs, Sotagliflozin came from deep chemical exploration. Lexicon Pharmaceuticals first developed it, aiming to bridge gut and kidney sugar absorption, and later pulled Sanofi into the picture for broad development and market reach. This journey tracked not just the science but also fierce regulatory debates, lengthy safety reviews, and patient advocacy at a time when needs far outpaced solutions.
Finding treatment balance remains a constant battle for many with diabetes. Sotagliflozin, branded as Zynquista in EU drug listings and known by molecular shorthand LX4211, tackles both SGLT1 in the intestine and SGLT2 in the kidney. Blocking SGLT1 reduces sugar spikes after eating; targeting SGLT2 pushes excess sugar out in urine. Clinical trials highlighted drops in hemoglobin A1c levels and modest weight loss. Studies in both type 1 and type 2 diabetes fueled excitement but also drew scrutiny, especially over diabetic ketoacidosis risk, a rare but serious complication. This dual inhibitor made headlines in 2019 through 2022 as the FDA and EMA considered—sometimes with reluctance—widening treatment options for a broad patient population dissatisfied with insulin-only tools. Zynquista filled a gap for those without access to multiple insulin doses, showing the market yearned for solutions that fit real-world lives.
Looking at its makeup, sotagliflozin stands out as a small molecule, white to off-white in appearance, and fairly stable at room temperature. It dissolves best in dimethyl sulfoxide (DMSO) and similar solvents, facing trouble in plain water. Its molecular formula, C21H23FO5S, supports a molecular weight close to 406.48 g/mol. The presence of a fluorine atom, aromatic rings, and a sulfur group contribute to both its oral bioavailability and kidney targeting. Analytical chemists use high-performance liquid chromatography (HPLC) and nuclear magnetic resonance (NMR) to check purity and identity, while storage under light-proof, moisture-controlled conditions keeps it from degrading on the shelf. Its melting point, usually between 82-85°C, signals a delicate solid suited for careful formulation work.
Packaging for sotagliflozin emphasizes strict labeling: strengths commonly include 100 mg or 200 mg tablets. Labels warn against use in severe kidney impairment, include blood glucose monitoring reminders, and list ketoacidosis as a rare danger. Dosage adjusts based on patient response, with guidance for both adults and adolescents. Specifications require active ingredient content within a narrow range—usually ±5%—and set strict limits for impurities like related substances and residual solvents. International pharmacopoeias outline chemical reference standards, and stability data drive both expiration dates and environmental storage requirements. Every batch includes a validated certificate of analysis and detailed safety data sheet for clinics, hospitals, and wholesalers.
Chemists synthesize sotagliflozin using a multistep process. The method starts with protected aromatic aldehyde derivatives, which undergo enantioselective allylation and fluorination. These steps build the carbon framework and ensure the right handedness—crucial for biological activity. Next, introduction of the thiofuran group follows, carried out in a controlled reaction with suitable bases and solvents. Final deprotection, purification by flash column chromatography, and crystallization from appropriate solvents help isolate the pure compound in good yield. Each step demands careful temperature control, inert atmospheres to avoid unwanted oxidation, and analytical checks to catch impurities before progressing. This route, refined over years, supports both small-batch clinical supply and scalable industrial production.
Dedicated research labs continue to test modifications to sotagliflozin’s chemical structure, seeking molecules with improved selectivity or fewer side effects. The fluorine group can be exchanged for other halogens, or the thiofuran moiety altered, yielding analogues with different profiles. Researchers also experiment with prodrug approaches—linking sotagliflozin to other chemical groups for improved absorption or slower release. Known reactions include nucleophilic substitution and oxidation at specific sites, helping fine-tune stability or targeting. These efforts open possibilities for next-generation dual inhibitors or related drugs for other metabolic disorders.
Sotagliflozin carries several identifiers across scientific literature and commercial listings. Its most common synonym remains LX4211, the code used during early development and clinical trials. The EU commercial market knows it as Zynquista, while some research texts refer to it as (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol. CAS registry number 1018899-04-1 backs up technical reference and purchase. No matter the name, the molecule’s structure and activity remain consistent, serving both analytical labs and clinical pharmacy shelves.
Working with sotagliflozin in a lab or clinic means following clear safety guidelines. Operators wear gloves, lab coats, and safety glasses to prevent skin or eye exposure. Powders require careful handling to avoid inhalation, with local ventilation for bulk processes. Spills are contained using inert absorbents, disposed of under hazardous chemical regulations. Labels include information for emergency responders and toxicology staff, emphasizing risks from accidental ingestion or inhalation. Hospitals and research facilities train staff not just in handling but in waste management, aiming to keep environmental release to a minimum. Shipping regulations set temperature and humidity limits; any deviation triggers inspection before patient use.
Sotagliflozin’s value lies not just in blood sugar numbers. For patients with type 1 diabetes, strict insulin management leaves little room for error. Kalorra, an active member of a diabetes online forum, found improved post-meal control and less frequent hypoglycemia after adding sotagliflozin to her routine—important for teens and adults trying to live “normal” lives. People with cardiovascular risk factors, including kidney function impairment, look for drugs that support heart and metabolic health together. European drug agencies have approved sotagliflozin for specific patient subgroups, and new studies keep expanding its reach into complex cases where standard therapies just don’t cut it. Research continues into its use alongside GLP-1 receptor agonists and in patients with overlapping heart failure, opening doors to multi-layered treatment strategies.
Big changes often start with small studies. Early work on sotagliflozin mapped glucose-lowering effects in animal tests, then expanded into phase I and II trials measuring safety and blood sugar impact in both healthy volunteers and diabetic subjects. Later, multi-center trials in the United States and Europe tracked long-term cardiovascular and renal outcomes, drawing robust data to answer safety and benefit questions. Academic labs now study genetic markers for the best responders, seeking to identify which patient genotypes benefit most. Meanwhile, new delivery systems—like subcutaneous depots or gastric-resistant coatings—could transform how patients take the drug, making adherence less of a chore. Publications in journals like “Diabetes Care” and “The Lancet” keep the broader medical community engaged in the ongoing debate over treatment standards and next steps.
Every new drug comes with risks. Animal studies for sotagliflozin examined acute and chronic toxicity, reproductive effects, and carcinogenic potential. Clinical trials monitored patients for electrolyte disturbances, urinary tract infections, ketoacidosis, and rare allergic reactions. Long-term safety data shows most patients tolerate the drug well, though those with impaired kidney function or unusual metabolic conditions need extra monitoring. Regulatory filings include extensive tables of adverse events, ongoing registry surveillance, and post-marketing studies aimed at catching late-onset effects. Epidemiologists work with real-world data from hospital records and insurance databases, flagging any signals that emerge after widespread rollout.
Sotagliflozin changed the conversation about dual-pathway drugs for diabetes. A few years ago, patients begged for tools that let them live with less restriction, less constant glucose tracking, and lower heart risk. That demand isn’t disappearing. As new trials move into patients with heart failure, obesity, and early-stage kidney disease, sotagliflozin sets expectations for what future metabolic drugs should offer: real impact on patient lives, tolerable safety, and easy integration with daily routines. Pharmaceutical teams are already engineering related compounds, pushing for triple-action molecules or smart-release designs. Health systems, stretched by rising diabetes rates, want these innovations not just for clinical trial superstars but for regular people coping with everyday ups and downs. Sotagliflozin won’t end diabetes, but it shows how practical chemistry and persistent patient focus can shift standards for years to come.
Sotagliflozin has given doctors and patients another option for tackling diabetes, a disease that only seems to get more common every year. What sets sotagliflozin apart comes from its dual action. Instead of focusing on a single route, this drug targets both the kidneys and the intestines to lower blood sugar levels. That means it blocks both SGLT1 and SGLT2 proteins, not just one like older drugs in the same family. By stopping these proteins from reabsorbing sugar, the body flushes more glucose out through urine and limits how much sugar enters the bloodstream after eating. For people living with type 1 or type 2 diabetes, this shift matters.
Living with diabetes isn’t just about watching sugar intake or remembering to inject insulin. The constant effort leaves many feeling stuck between numbers and restrictions. Sotagliflozin offers a new angle, especially for those who can’t hit their targets with regular treatments. It helps reduce blood sugar, and clinical studies reveal another benefit — a drop in body weight and blood pressure. These changes add up since extra weight and high blood pressure make diabetes harder to manage and trigger complications.
Research, including the SOLOIST-WHF and SCORED trials, connects sotagliflozin to fewer hospital visits for heart failure and kidney disease in adults living with diabetes and cardiovascular risks. As someone who has spent years watching loved ones struggle through every new pill and shot, options that look out for both blood sugar and the heart feel like a real step forward. Modern life brings high stress, less exercise, and unhealthy eating, all of which multiply risks. Soultions that get people healthier on more than one front offer hope.
No drug comes without concerns. Sotagliflozin can lead to a greater risk of urinary tract infections or genital mycotic infections. Since it makes the kidneys work harder to push out sugar, dehydration and drops in blood pressure become real risks, especially for seniors or those already on diuretics. For people with type 1 diabetes, stopping doctors from prescribing it too freely becomes important because it can raise the risk of diabetic ketoacidosis, a serious and sometimes life-threatening complication.
Doctors and patients have to work closely with this medicine. Monitoring matters. Tests for kidney function, watching for faintness, and making sure patients report any early symptoms of infection should become routine. Education becomes part of the treatment because understanding side effects means patients can act fast, before trouble starts. In many clinics, regular updates and proactive messages from the care team close the gap.
No single drug solves everything. Sotagliflozin shines most when used as part of a bigger plan — diet, exercise, regular monitoring, and medication adjustments. Technology like continuous glucose monitors can make spotting trends and problems easier, putting more power into patients’ hands. Insurance coverage, especially in places without robust healthcare, limits who can benefit. Efforts to bring prices down, expand access, and educate more communities could unlock the promise sotagliflozin brings. Reaching for better health takes more than one tool.
Sotagliflozin keeps popping up in conversations about type 1 and type 2 diabetes care. I’ve seen family and friends roll their eyes at the growing laundry list of new drugs, but this one works in a way that stands out compared to the rest. It blocks two sugar transporters—SGLT1 and SGLT2—whereas most similar drugs just go after SGLT2. Not a flashy topic, but it matters.
Most folks think of sugar hitting the bloodstream through food, and that’s not wrong, but the story gets complicated once you look at how the kidneys and gut handle blood sugar. SGLT2 lives in the kidneys and pulls sugar back into the blood before it leaves the body through urine. On the other hand, SGLT1 sits in the intestine and brings sugar into the body from food.
Sotagliflozin takes on both. By blocking SGLT2, it helps send extra sugar out through urine. By blocking SGLT1, it slows how quickly sugar from food gets into the body. A two-pronged approach like this can mean steadier blood sugar without needing massive doses of insulin. For some people, the difference hits hard—less worry about post-meal spikes, even fewer lows.
Clinical trials and real-world studies back up what the mechanism suggests. Folks using it see lower A1C levels, which signals average blood sugar trending better. Less glucose swings give a break to blood vessels and nerves—those are areas where high blood sugar causes lifelong damage, especially in the feet, eyes, and kidneys.
Other SGLT2-only drugs lower A1C but don’t slow down gut sugar absorption. People I know who use sotagliflozin describe fewer “sugar crashes” after eating, which lines up with what researchers see in studies. The gut effect really puts the brakes on roller-coaster blood sugar after meals.
The drug also helps with dropping a few pounds, which makes sense. More sugar leaving the body means less for the scale to hold onto. Weight control ties into better heart health, and that’s another angle sotagliflozin covers. Studies show lower risks of heart failure and fewer kidney issues over time. New cases of these complications can make life way harder, so cutting them off at the pass speaks louder than endless lab numbers.
This isn’t a magic fix. More sugar in urine means more frequent trips to the bathroom and—let’s not dance around it—infections can show up. Yeast and urinary tract infections pop up more, so people must stay aware and check in with their doctor at warning signs. Stomach upsets also come up when the gut holds onto sugar for longer.
Doctors, patients, and families end up weighing these risks against the benefits. Many would rather live with side effects than nerve pain, vision loss, or kidney failure. But sotagliflozin doesn’t replace healthy eating, exercise, or routine insulin for type 1—most people still work with their healthcare team to get the most out of all the tools available.
People deserve the real story behind new drugs like sotagliflozin. Healthcare teams who talk openly about both the science and daily experience help build the kind of trust that leads to better health choices. Real people need real answers, and sotagliflozin changes the landscape for diabetes—offering more than just lab results by aiming for steadier control and peace of mind.
Sotagliflozin serves as a treatment for adults dealing with type 1 and type 2 diabetes. It works by blocking two proteins—SGLT1 and SGLT2—that help the kidneys and intestines absorb glucose. The end result is often better blood sugar control. As someone who has spent years talking with patients and doctors about diabetes medications, I appreciate how these new therapies can offer more freedom. Still, no drug is perfect, and like most medications, this one comes with its own list of side effects.
Digestive discomfort tends to top the list. Diarrhea hits some folks pretty quickly, especially at the beginning. Nobody enjoys planning their day around bathroom breaks. This reaction connects directly to how the drug blocks glucose absorption in the gut. I’ve seen people try to tough it out, hoping things get better, but sometimes adjustments to timing or food choices can help ease this issue.
Urinary tract infections (UTIs) and yeast infections also come up more often in folks taking Sotagliflozin. High sugar in the urine offers a breeding ground for bacteria and fungi. Women talk about the itching, burning, and frustration of dealing with these infections. Men aren’t completely off the hook either, especially those who are uncircumcised or have a history of these infections. Drinking more water and practicing good hygiene goes a long way here, but recurrent problems should always lead to a real conversation with your doctor.
Most people also see more frequent urination. This is a direct effect of the body passing extra glucose out through urine. More trips to the restroom mean some people notice increased thirst. Over time, that can mean slight dehydration, especially if you already live in a hot climate or have trouble drinking enough fluids. I always suggest carrying a water bottle, and trusted nurses often remind patients to check for signs like dry mouth or dark urine as early warning signs.
Ketoacidosis represents a rare but critical risk for anyone taking this medication, even folks with type 2 diabetes. This problem shows up as nausea, vomiting, trouble breathing, and confusion. Unlike the classic version that develops only with sky-high blood sugars, SGLT inhibitors like Sotagliflozin can trigger ketoacidosis even when blood sugars look close to normal. No one should “tough it out” in this case—immediate medical care is essential. Many endocrinologists are now advising patients to check for ketones, especially during illness or fasting.
People with kidney problems must use extra care. This drug relies on healthy kidneys to flush out glucose. If kidneys slow down or fail, the risk of side effects ramps up quickly. Doctors screen for kidney function before and during treatment. People with known kidney disease often need a completely different approach.
Sotagliflozin gives people another tool to manage blood sugar, which helps prevent long-term complications from diabetes. At the same time, the side effect profile means paying close attention to your body always matters. Open lines of communication with health care providers make a difference—report unusual symptoms early and ask questions about how the medication fits into your life. Diabetes demands teamwork between people living with it and those who treat it.
For more details, resources such as the U.S. FDA and the American Diabetes Association provide up-to-date guidance and recommendations. Staying informed helps everyone make choices that support their health and well-being.
For many people with diabetes, keeping blood sugar in check matters a lot. Medications change lives, but kidney function often complicates the search for the right one. Sotagliflozin, known as a dual SGLT1 and SGLT2 inhibitor, shows promise for blood glucose control. But the real question keeps coming up: can people with kidney problems count on this drug without risking serious harm?
Clinical trials always paint a mixed picture for medicines working on kidneys. A 2020 study published in The Lancet showed sotagliflozin cut down on hospital stays for heart failure in type 2 diabetes patients. The twist: not everyone in the study had advanced kidney disease. Actually, the biggest kidney benefits showed up in people with only mildly decreased kidney function, not those with the worst kidney numbers. When kidney function drops (eGFR below 30 mL/min/1.73 m2), sotagliflozin’s blood sugar-lowering effect takes a big hit. The risk of side effects, including dehydration and urinary tract infections, climbs higher in this group too.
Folks with kidney problems already juggle careful food choices, endless doctor appointments, and constant blood work. Adding a drug that pushes more sugar out through urine might sound good, but hard-hit kidneys can’t always keep up. Many people tell their doctors they feel more tired and dizzy after starting these types of medicines. Kidney experts flag the risk of sudden declines in kidney function, especially if someone gets sick or needs to stop eating and drinking for any reason.
Doctors check two things before writing the prescription: kidney test results and the risk of side effects. Official guidelines, including those from the American Diabetes Association, recommend SGLT2 inhibitors for patients with kidney issues, but only above a certain kidney function threshold. Sotagliflozin hasn’t been as widely approved or adopted as similar drugs like dapagliflozin or empagliflozin, so many healthcare providers stay cautious. Some skip it entirely for anyone with an eGFR under 30. There’s also the issue of cost and insurance—not every patient gets access, even if it might help.
Patients deserve a treatment plan that doesn’t add more risks. Strong communication between kidney specialists, diabetes doctors, and pharmacists helps spot trouble early. Routine follow-up, close monitoring of blood pressure, and patient education make a world of difference. Most importantly, anyone starting sotagliflozin with less-than-perfect kidneys should know the warning signs: dizziness, swelling, sudden weight gain or loss, and more frequent infections. If something feels off, people should call or see a doctor without waiting for a scheduled visit.
New research focusing on people with more advanced kidney disease remains crucial. Everyone—doctors, researchers, patients—has a role in sharing real-world results, so information stays accurate and grounded. Medicines like sotagliflozin bring hope, but everyone has to remember that kidney health plays by its own rules.
Every person with diabetes juggles their own puzzle pieces. Many already take a handful of pills or insulin injections each day, with the hope that the next adjustment means fewer complications. Sotagliflozin, showing up under names like Inpefa and Zynquista, landed on the scene to help manage both type 1 and type 2 diabetes. If you know someone who takes metformin, sulfonylureas, or insulin, the question about mixing sotagliflozin with these staples isn’t just academic. People want to know if these combinations truly make life easier—or if they cause more trouble than they’re worth.
Doctors often pair up diabetes medications to chase better blood sugar numbers. Metformin stays at the top of the chart, often as a starting point. Research shows patients taking metformin with sotagliflozin can see a bigger drop in their A1C, which is that long-term blood sugar test every diabetic circles on the calendar. At the same time, there’s a reduced risk of hypoglycemia compared to the mix of insulin with some drugs like sulfonylureas.
Adding sotagliflozin isn’t just about blood sugar—some studies highlight improvements in weight and blood pressure, especially in people with type 2 diabetes. Anyone living with heart or kidney problems pays extra attention here, since sotagliflozin’s dual action on both SGLT1 and SGLT2 helps the kidneys dump more sugar and salt in urine, which can lighten the load on the heart. That’s something doctors and patients both value in day-to-day life.
Mixing pills brings its own kind of baggage. Some side effects—like dehydration, urinary tract infections, or yeast problems—pop up more when somebody adds an SGLT-inhibitor. Pairing with insulin or secretagogues (like glipizide or gliclazide) puts people at greater risk for a dangerous dip in blood sugar. From what I’ve seen, it takes teamwork with a doctor to keep close tabs on symptoms and tweak dosages, especially for those who get sick easily or already deal with kidney trouble.
Diabetic ketoacidosis (DKA), though rare with type 2 diabetes, matters a lot for people with type 1. Some headlines flagged this risk early on. Realistically, I know people can catch early warning signs if they test for ketones and seek help fast enough. Stomach flu or skipping food while taking these combos isn’t a small thing—those are the moments when close communication with a clinic means everything.
Checking blood sugar more often helps, especially in the first months after adding sotagliflozin. It sounds simple, but actually doing it makes all the difference. Drinking enough water and recognizing signs of infection can head off bigger problems. Health teams often start with lower doses and talk about ditching or adjusting any pills that increase low blood sugar risk. Sharing honest updates about diet, exercise, or any new symptoms lets doctors respond without delay.
Access matters, too. Insurance rules or lack of access to new meds can stall out even the best plans. Patient assistance programs and partnerships between patients and diabetes educators make room for safe, realistic use. At the end of the day, this isn’t just about mixing up a new pill. It’s about finding small wins so people with diabetes can live longer, stronger, and with fewer disruptions.
| Names | |
| Preferred IUPAC name | (2S,3R,4R,5S,6R)-2-(4-ethoxybenzyl)-6-(4-glucopyranosyloxybenzyl)oxane-3,4,5-triol |
| Other names |
LX-4211 Zynquista |
| Pronunciation | /soʊˌtæɡlɪˈfloʊzɪn/ |
| Identifiers | |
| CAS Number | 1018899-04-1 |
| Beilstein Reference | 14223140 |
| ChEBI | CHEBI:139494 |
| ChEMBL | CHEMBL2105717 |
| ChemSpider | 1266011 |
| DrugBank | DB14526 |
| ECHA InfoCard | DC382618-ECHA |
| EC Number | Sotagliflozin does not have an EC Number |
| Gmelin Reference | 969219 |
| KEGG | D11136 |
| MeSH | D000071246 |
| PubChem CID | 24812707 |
| RTECS number | GVG4U4P4PV |
| UNII | 6Z15ZO65ZT |
| UN number | UNII: 3P7828O4LO |
| Properties | |
| Chemical formula | C21H25FO5S |
| Molar mass | 482.561 g/mol |
| Appearance | White to off-white powder |
| Odor | Odorless |
| Density | 1.31 g/cm³ |
| Solubility in water | Soluble in DMSO, not in water |
| log P | 2.2 |
| Acidity (pKa) | pKa = 13.68 |
| Basicity (pKb) | pKb = 5.45 |
| Magnetic susceptibility (χ) | -73.0e-6 cm³/mol |
| Refractive index (nD) | 1.77 |
| Dipole moment | 3.98 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 293.2 J·mol⁻¹·K⁻¹ |
| Std enthalpy of combustion (ΔcH⦵298) | −11320 kJ·mol⁻¹ |
| Pharmacology | |
| ATC code | A10BK04 |
| Hazards | |
| Main hazards | May cause hypoglycemia, dehydration, urinary tract infections, and genital mycotic infections. |
| GHS labelling | **"Not a hazardous substance or mixture according to the Globally Harmonized System (GHS)."** |
| Pictograms | GHX87 |
| Signal word | Warning |
| Hazard statements | No hazard statements. |
| Precautionary statements | Keep out of reach of children. |
| Lethal dose or concentration | LD₅₀ (rat, oral): >2000 mg/kg |
| LD50 (median dose) | LD50 (median dose) of Sotagliflozin: ">2000 mg/kg (rat, oral) |
| PEL (Permissible) | PEL: Not established |
| REL (Recommended) | 100 mg once daily |
| IDLH (Immediate danger) | Not Established |
| Related compounds | |
| Related compounds |
Canagliflozin Dapagliflozin Empagliflozin Ertugliflozin Ipragliflozin Luseogliflozin Tofogliflozin Remogliflozin |
